5 research outputs found
Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)
Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients. Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical characteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected. Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metastases' resection was 87.35 months (ICR: 1.51-332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13-78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13-3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22-4.86], p 0.01). Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the performance of a total pancreatectomy in order to improve survival. (C) 2021 The Authors. Published by Elsevier Ltd
Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)
Background and objectives: Recurrent isolated pancreatic metastasis from Renal Cell Carcinoma (RCC) after pancreatic resection is rare. The purpose of our study is to describe a series of cases of relapse of pancreatic metastasis from renal cancer in the pancreatic remnant and its surgical treatment with a repeated pancreatic resection, and to analyse the results of both overall and disease -free survival. Methods: Multicenter retrospective study of patients undergoing pancreatic resection for RCC pancreatic metastases, from January 2010 to May 2020. Patients were grouped into two groups depending on whether they received a single pancreatic resection (SPS) or iterative pancreatic resection. Data on short and long-term outcome after pancreatic resection were collected. Results: The study included 131 pancreatic resections performed in 116 patients. Thus, iterative pancreatic surgery (IPS) was performed in 15 patients. The mean length of time between the first pancreatic surgery and the second was 48.9 months (95 % CI: 22.2-56.9). There were no differences in the rate of postoperative complications. The DFS rates at 1, 3 and 5 years were 86 %, 78 % and 78 % vs 75 %, 50 % and 37 % in the IPS and SPS group respectively (p = 0.179). OS rates at 1, 3, 5 and 7 years were 100 %, 100 %, 100 % and 75 % in the IPS group vs 95 %, 85 %, 80 % and 68 % in the SPS group (p = 0.895). Conclusion: Repeated pancreatic resection in case of relapse of pancreatic metastasis of RCC in the pancreatic remnant is justified, since it achieves OS results similar to those obtained after the first resection
Pancreatic metastases from renal cell carcinoma: postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)
Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients. Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical characteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected. Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metastases' resection was 87.35 months (ICR: 1.51-332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13-78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13-3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22-4.86], p 0.01). Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the performance of a total pancreatectomy in order to improve survival
Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)
Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study
is to evaluate the short and long-term results of a multicenter series in order to determine the effect of
surgical treatment on the prognosis of these patients.
Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases,
from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical char-
acteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on
short and long-term evolution after pancreatic resection were collected.
Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metas-
tases’ resection was 87.35 months (ICR: 1.51e332.55). Distal pancreatectomy was the most performed
technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo
greater than IIIa in 14 %). The median follow-up time was 43 months (13e78). Overall survival (OS) rates
at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and
5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free
interval of less than 10 years (2.05 [1.13e3.72], p 0.02) and a history of previous extrapancreatic
metastasis (2.44 [1.22e4.86], p 0.01).
Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve
higher overall survival and disease-free survival, even if extrapancreatic metastases were previously
removed. The existence of intrapancreatic multifocal compromise does not always warrant the perfor-
mance of a total pancreatectomy in order to improve survival
Prognostic value of pre-operative systemic immune-inflammation index and platelet to lymphocyte ratio in peritoneal carcinomatosis of ovarian origin
Background and objectives: The aim of this study was to investigate the impact of systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) on the survival outcomes of patients who underwent to cytoreductive surgery (CRS) and HIPEC for ovarian peritoneal carcinomatosis.
Methods: A retrospective analysis of 68 cases following surgery at our department between 2015 and 2020 was performed. Receiver Operating Characteristic (ROC) curve was used with Youden index to calculate the optimal cutoff values for SII, PLR and NLR.
Results: Univariate analysis revealed that high preoperative values of SII, PLR and NLR were correlated with worse overall survival (OS) and disease-free survival (DFS) in these patients. In the multivariable analysis, high SII was recognized as an independent prognostic factor for OS (CI 95%: 0.002- 3.835, p = 0.097) and high PLR was recognized as an independent prognostic factor for DFS (CI 95%: 0.253–2.248, p = 0.007).
Conclusion: SII and PLR could be useful prognostic tools to predict outcomes of patients who underwent to CRS and HIPEC for ovarian peritoneal carcinomatosis.Trasfondo y objetivos: El objetivo de este estudio fue investigar el impacto del índice de inflamación inmune sistémica (SII), la proporción de plaquetas a linfocitos (PLR) y la proporción de neutrófilos a linfocitos (NLR) en los resultados de supervivencia de los pacientes que se sometieron a cirugía citorreductora (CRS) y HIPEC para carcinomatosis peritoneal de ovario.
Métodos: Se realizó un análisis retrospectivo de 68 casos tras cirugía en nuestro servicio entre 2015 y 2020. Se utilizó la curva de característica operativa del receptor (ROC) con el índice de Youden para calcular los valores de corte óptimos para SII, PLR y NLR.
Resultados: El análisis univariante reveló que los valores preoperatorios altos de SII, PLR y NLR se correlacionaron con una peor supervivencia general (SG) y supervivencia libre de enfermedad (DFS) en estos pacientes. En el análisis multivariable, el SII elevado se reconoció como factor pronóstico independiente de SG (IC 95 %: 0,002-3,835, p = 0,097) y el PLR alto se reconoció como factor pronóstico independiente de SLE (IC 95 %: 0,253–2,248, p = 0,007).
Conclusión: SII y PLR podrían ser herramientas de pronóstico útiles para predecir los resultados de los pacientes que se sometieron a CRS e HIPEC por carcinomatosis peritoneal de ovario.Financiación de acceso abierto gracias al acuerdo CRUE-CSIC con Elsevier.peerReviewe